Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03338348
• Other study ID #: AMLSG 24-15
• Status: Completed
• Phase: Phase 2
• Start date: April 19, 2018
• Est. completion date: October 31, 2019

Study information

• Verified date: October 2020
• Source: University of Ulm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2. An initial safety run-in phase of the study will be performed administering the study drug vosaroxin with azacitidine in up to 18 patients. After completion of the run-in phase, toxicity and response data will be provided to the external Data and Safety Monitoring Board (DSMB) and the Trial Committee by the Coordinating Investigator. The Trial Committee will decide on the basis of these data and the recommendation of the DSMB on dose modification and the vosaroxin dose for the phase II part of the study, which will include 150 patients in total.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: October 31, 2019
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

1. Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)

2. Patients =60 years of age

3. No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis for up to 10 days during the diagnostic screening phase; patients may have received prior therapy for myelodysplastic syndrome different from hypomethylating agents

4. ECOG performance status =2

5. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 3 month after the last dose of vosaroxin)

6. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).

7. Female patients of reproductive age must agree to avoid getting pregnant while on therapy and for 3 months after the last dose of vosaroxin.

8. Women of child-bearing potential including the female partners of the male patients must either commit to continued abstinence from heterosexual intercourse or apply two acceptable methods of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.

9. Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for three months after the last dose of chemotherapy)

10. Willing to adhere to protocol specific requirements

11. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out

Exclusion Criteria:

1. Known or suspected hypersensitivity to the study drugs and/or any excipients

2. Favorable genetics: t(15;17)(q22;q12), PML-RARA; t(8;21)(q22;q22), RUNX1-RUNX1T1; inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11; mutated NPM1 without FLT3-ITD or with FLT3-ITDlow

3. Prior treatment for AML except hydroxyurea

4. Prior treatment for MDS with hypomethylating agents

5. ECOG performance status >2

6. Patients who are not eligible for intensive chemotherapy

7. Inadequate cardiac, hepatic and/or renal function at the Screening Visit defined as:

• Ejection fraction <40% confirmed by echocardiography

• Creatinine >1.5x upper normal serum level

• Total bilirubin, AST or ALT >1.5 upper normal serum level

8. Active central nervous system involvement

9. Any clinically significant, advanced or unstable disease or history of that may interfere with primary or secondary variable evaluations or put the patient at special risk, such as:

• Myocardial infarction, unstable angina within 3 months before screening

• Heart failure NYHA III/IV

• Severe obstructive or restrictive ventilation disorder

• Uncontrolled infection

10. Severe neurological or psychiatric disorder interfering with ability of giving an informed consent

11. Currently receiving a therapy not permitted during the study, as defined in Section 10.5.4

12. Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.

13. Known history of positive test for Hepatitis B surface Antigen (HBsAg) or hepatitis C antibody or history of positive test for Human Immunodeficiency Virus (HIV)

14. Hematological disorder independent of leukemia

15. No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation

16. No consent for biobanking

17. Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study

18. Patients known or suspected of not being able to comply with this trial protocol

19. Patients of childbearing potential not willing to use adequate contraception during study and 3 months after last dose of therapy

20. Breast feeding women or women with a positive pregnancy test at Screening visit

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Anemia, Refractory, with Excess of Blasts
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Vosaroxin
Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
• Azacitidine
Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression.

Locations

Country	Name	City	State
Germany	Kliniken Essen-Süd, Evang. Krankenhaus Essen-Werden gGmbH	Essen
Germany	Klinikum Oldenburg, Klinik für Innere Medizin II	Oldenburg
Germany	University Hospital Ulm	Ulm

Sponsors (2)

Lead Sponsor	Collaborator
University of Ulm	Sunesis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of complete remission (CR) and CR with incomplete blood count recovery (CRi)	Efficacy assessments	2 months
Secondary	CR and CRi in a pre-defined subgroup analysis in patients with complex karyotype	Efficacy assessments	2 months
Secondary	CR and rate of combined CR/CRi and CR with negativity for minimal residual disease (CRMRD-)	Efficacy assessments	2 months
Secondary	Duration of response (DOR)	Efficacy assessments	4 years
Secondary	Event-free survival (EFS)	Efficacy assessments	4 years
Secondary	Overall survival (OS)	Efficacy assessments	4 years
Secondary	30-day and 60-day mortality	Safety assessments	30 and 60 days
Secondary	Incidence and intensity of adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version v4.0	Safety assessments	12 months
Secondary	Assessment of Quality of life by the EORTC Quality of Life Core Questionnaire (QLQ-C30)	Quality of life	4 years